media – Page 28 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Triple Dose Of Ozempic Safe, More Effective For Weight Loss

By Dennis Thompson HealthDay ReporterTUESDAY, Sept. 16, 2025 (HealthDay News) — A triple-sized weekly dose of Ozempic works better to help people with obesity shed excess pounds without significant side effects, new clinical trial results show. Obese folks lost more weight taking 7.2 mg of semaglutide (Ozempic/Wegovy) a week than those taking either the currently approved dose of 2.4 mg or a placebo, researchers reported Sept. 14 in The Lancet Diabetes & Endocrinology. The results “suggest that a higher dose of semaglutide up to 7.2 mg per week could be used to achieve greater clinical benefits in people not reaching therapeutic goals with once-weekly semaglutide 2.4 mg,” concluded a team led by Dr. Sean Wharton, leader of the Wharton Medical Clinic for Weight and Diabetes Management in Ontario, Canada. Researchers tested the triple-dose of semaglutide in two clinical trials, one involving people with obesity and the other in people with ...
- Source: drugdu
- 89
- September 17, 2025
【EXPERT Q&A】Specifically, what are Class II medical devices?

Drugdu.com expert’s response: Class II medical devices refer to medical devices with moderate risk that require strict control and management to ensure their safety and effectiveness. Below is a detailed explanation of Class II medical devices: I. Definition and Risk Level Definition: Class II medical devices are those whose safety and effectiveness should be controlled. These devices are typically used for the prevention, diagnosis, monitoring, treatment, or alleviation of diseases in human organs, tissues, or body fluids outside the body, employing various technological means and potentially posing a moderate risk to humans. Risk Level: The risk level of Class II medical devices falls between that of Class I low-risk medical devices and Class III high-risk medical devices. Class I medical devices have a low degree of risk and can be managed through routine measures to ensure their safety and effectiveness. In contrast, Class III medical devices carry a higher risk ...
- Source: drugdu
- 132
- September 17, 2025
The birth of the youngest pharmaceutical company worth hundreds of billions of yuan

The World Lung Cancer Conference (WCLC), a leading global conference in the field of lung cancer treatment, has always been a central arena for innovative pharmaceutical companies to compete. At this year’s WCLC, several innovative Chinese pharmaceutical companies made their mark, with Baili Tianheng undoubtedly the most prominent. Its core product, the world’s first EGFR×HER3 bispecific ADC drug BL-B01D1 (Iza-bren) combined with osimertinib in the treatment of EGFR-mutated non-small cell lung cancer, has achieved an objective response rate (ORR) of 100%, with far-leading efficacy data. It has also achieved a historic breakthrough of a median progression-free survival (mPFS) of over 12 months in monotherapy. As of the close of September 12, the share price of Baili Tianheng’s A shares closed at 349.79 yuan per share, and the company’s total market value exceeded 140 billion yuan, making it the third innovative pharmaceutical company in the A-share market to join the “100 ...
- Source: drugdu
- 136
- September 16, 2025
Kexing Pharma partners with Thousand Oaks Biopharmaceuticals to enter the European and American biosimilar markets

Recently, Kexing Pharma have reached a strategic cooperation with Shanghai Thousand Oaks Biopharmaceutical Co., Ltd. (hereinafter referred to as “Thousand Oaks Bio”) to jointly develop the KXBS001 biosimilar, officially entering the European and American biosimilars market. The European Medicines Agency (EMA) recently released a draft plan to streamline the review process for biosimilar drug development, potentially opening a “fast track” to the EU market for domestic pharmaceutical companies. According to an IQVIA research report, the EU, as the world’s leading biosimilar market (accounting for approximately 40% of its value), will have no corresponding biosimilars in development for approximately 71% of original biosimilars whose patents expire between 2024 and 2030, presenting a significant market opportunity. Kexing Pharma adheres to the “innovation + internationalization” strategy and has formed full-chain innovation capabilities for its antibody technology platform, with a portfolio of more than ten new drugs in the fields of antiviral, tumor, and ...
- Source: drugdu
- 75
- September 16, 2025
Zhengda Tianqing’s new drug Qinglishu approved for marketing

　　Xinhua Finance, Nanjing, September 15 (Reporter Zhu Cheng) Recently, the official website of the National Medical Products Administration showed that the injectable degarelix acetate (trademark name: Qinglishu) independently developed by China Biopharmaceutical ‘s core enterprise, Zhengda Tianqing Pharmaceutical Group, has been approved for marketing for prostate cancer patients who need androgen deprivation therapy. 　　Zhengda Tianqing’s degarelix acetate has been approved in the EU market, becoming the world’s first generic drug, and has also received provisional approval in the US. During the domestic review process, Zhengda Tianqing also launched a patent challenge, successfully invalidating two core claims of the original drug. This product also became the first drug to receive a 12-month exclusivity period since the implementation of my country’s early resolution mechanism for pharmaceutical patent disputes. 　　The early resolution mechanism for drug patent disputes, also known as the drug patent linkage system, is a mechanism to balance the development of ...
- Source: drugdu
- 68
- September 16, 2025
Sinovac Biotech partners with Auscon Biopharmaceuticals to enter the European and American biosimilar markets

　　Shanghai Securities News China SecuritiesNews (Reporter Yang Ye, Zhao Binbin) Recently, Sinovac BiotechWe have reached a strategic cooperation with Shanghai Auscon Biopharmaceutical Co., Ltd. (hereinafter referred to as “Auscon Bio”) to jointly develop the KXBS001 biosimilar, officially entering the European and American biosimilars market. 　　The European Medicines Agency (EMA) recently released a draft plan to streamline the review process for biosimilar drug development, potentially opening a “fast track” to the EU market for domestic pharmaceutical companies. According to an IQVIA research report, the EU, as the world’s leading biosimilar market (accounting for approximately 40% of its value), will have no corresponding biosimilars in development for approximately 71% of original biosimilars whose patents expire between 2024 and 2030, presenting a significant market opportunity. 　　Sinovac Biotech adheres to the “innovation + internationalization” strategy and has formed full-chain innovation capabilities for its antibody technology platform, with a portfolio of more than ten new ...
- Source: drugdu
- 85
- September 16, 2025
MEDICALL EXPO

Organiser: Messe Düsseldorf GmbH (Germany) Time：September 19-21, 2025 address：Plot No. 25, 27, 28, 29, Knowledge Park II, Greater Noida, Uttar Pradesh 201306 or 201308, India Exhibition hall：Greater Noida Product range: Medical Technology/Electronic Medical Products, Equipment, and Systems Exhibition Area Diagnostic and Imaging Products, Equipment, and Systems Exhibition Area Portable Physical Therapy and Orthopedic Products, Equipment, and Systems Exhibition Area Surgical Products, Equipment, and Systems Exhibition Area Hygiene and Disinfection Products, Disposable Supplies Exhibition Area Medical Technology/Electronic Medical Products, Equipment, and Systems Exhibition Area Diagnostic and Imaging Products, Equipment, and Systems Exhibition Area Portable Physical Therapy and Orthopedic Products, Equipment, and Systems Exhibition Area Surgical Products, Equipment, and Systems Exhibition Area Hygiene and Disinfection Products, Disposable Supplies Exhibition Area Rehabilitation Devices and Equipment Exhibition Area About MEDICALL EXPO： The MEDICALL EXPO India is one of the most professional medical equipment exhibitions in India and South Asia. Organized by Messe ...
- Source: drugdu
- 140
- September 16, 2025
Novartis and Monte Rosa Therapeutics Announce $5.7 Billion Licensing Agreement Deal for Protein Degraders

Novartis announced a licensing agreement with Monte Rosa Therapeutics valued upwards of $5.7 billion that aims at developing drugs for immune-mediated diseases. “We are pleased to expand our collaboration with Monte Rosa Therapeutics, building on the strong foundation and progress established through the VAV1 program,” said Fiona Marshall, Ph.D., president of biomedical research at Novartis. “This new agreement underscores our commitment to advancing targeted protein degradation as a promising approach to address immune-mediated diseases with high unmet need. We believe Monte Rosa’s QuEEN platform has the potential to uncover new insights in this field. We look forward to working together to translate these insights into transformative therapies for patients.”2 What are the details of the deal? Under the terms of the agreement, Novartis will pay Monte Rosa an upfront payment of $120 million (along with holding the potential to earn milestone payments and royalties), which brings the total to $5.7 ...
- Source: drugdu
- 123
- September 16, 2025
Bariatric Fusion Vitamins Pulled for Missing Child-Safe Caps

MONDAY, Sept. 15, 2025 (HealthDay News) — About 4,700 bottles of Bariatric Fusion iron-containing multivitamins have been recalled because packaging does not meet federal safety standards, according to the U.S. Consumer Product Safety Commission (CPSC). The bottles, sold online at Amazon.com, bariatricfusion.com and other sites between January and June 2025, were made without child-resistant caps. Without this protection, children could open the bottles and swallow the vitamins, which contain high levels of iron. Accidental iron poisoning in children can cause serious injury or death. The recall involves: High ADEK multivitamin capsules (90- and 270-count bottles) One Per Day bariatric multivitamin capsules (90-count bottle) All recalled bottles contain 45 mg of iron and can be identified by lot numbers 0066J4, 0065J4, 0453B5 or 0370B5, printed on the bottom. Only bottles with smooth caps (no “push down & turn” embossing) are part of the recall. So far, no injuries have been reported, ...
- Source: drugdu
- 107
- September 16, 2025
Smoking raises the risk of all subtypes of type 2 diabetes

The characteristics of type 2 diabetes vary from patient to patient and it has been proposed that the condition is made up of four subtypes. Now, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that smoking increases the risk of the condition, regardless of subtype. The researchers in Sweden, Norway and Finland also found that people with a genetic susceptibility to develop diabetes seem more vulnerable to the adverse effects of smoking. It has previously been suggested that type 2 diabetes (T2D) can be divided into the following subtypes: SIRD (severe insulin-resistant diabetes), characterised by insulin resistance (where the body’s cells don’t respond to properly to insulin and can’t easily take up glucose from the blood); SIDD (severe insulin-deficient diabetes), characterised by a lack of insulin; MOD (mild obesity-related diabetes), associated with obesity and ...
- Source: drugdu
- 121
- September 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.